Evotec will make use of its drug discovery expertise and technologies to identify small molecules against a selected number of targets, which will be progressed through lead optimization to a pre-clinical candidate.
Evotec will receive research funding and will be further rewarded for research collaboration with early stage discovery, preclinical and clinical milestones.
The company will also be awarded royalties based on net sales of any approved drugs from the collaboration.
Evotec CEO Dr Werner Lanthaler said the integrated drug discovery deal showcases their expertise coupled with industry leading platform.
The financial details of the deal, however, have not been disclosed.